Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06835919 ADME and absolute bioavailability microtracer study in healthy men
NL-OMON49734Phase 1Withdrawn
- Sponsor
- Pfizer
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PF-06835919 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Pfizer. Primary endpoint: Mass balance recovery of radioactivity. Planned start Aug 2020; status: withdrawn.
02
Drugs
PF-06835919
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NL-OMON49734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49734.